Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response

详细信息    查看全文

• 作者：Noriko Kamata ; Nobuhide Oshitani ; Kenji Watanabe…
• 关键词：Crohn’s disease ; Infliximab ; Loss of response ; Elemental diet
• 刊名：Digestive Diseases and Sciences
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：60
• 期：5
• 页码：1382-1388
• 全文大小：576 KB
• 参考文献：1.Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337:1029-035.View Article PubMed
  2.Hanauer SB, Fegan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s diseasee: the ACCENT I randomized trial. Lancet. 2002;359:1541-549.View Article PubMed
  3.Bhatia JK, Korelitz BI, Panagopoulos G, et al. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn’s disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol. 2007;41:677-81.View Article PubMed
  4.Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in CD. Inflamm Bowel Dis. 2009;15:1295-301.View Article PubMed
  5.Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52-5.View Article PubMed
  6.Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;15:1383-395.View Article
  7.Mackey AC, Green L, Leptak C. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-88.View Article PubMed
  8.Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet-as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333-400.View Article PubMed
  9.Tanaka T, Takahama K, Kimura T, et al. Effect of concurrent elemental diet on infliximab treatment for Crohn’s disease. J Gastroenterol Hepatol. 2006;21:1143-149.View Article PubMed
  10.Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013;58:1329-334.View Article PubMed Central PubMed
  11.Satsangi J, Silverberg MS, Vermeire S. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.View Article PubMed Central PubMed
  12.Matsueda K, Shoda R, Takazoe M, et al. Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn’s disease: Japanese Cooperative Crohn’s Disease Study. J Gastroenterol. 1995;30:91-4.PubMed
  13.Hirakawa H, Fukuda Y, Tanida N, et al. Home elemental enteral hyperalimentation (HEEH) for maintenance of remission in patients with Crohn’s disease. Gastroenterol Jpn. 1993;28:379-84.PubMed
  14.Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut. 1996;38:543-48.View Article PubMed Central PubMed
  15.Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760-67.View Article PubMed
  16.Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol.. 2006;4:1248-254.View Article PubMed
  17.Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40-7.View Article PubMed Central PubMed
  18.Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962-71.View Article PubMed
  19.D’Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and hot to predict response? Am J Gastroenterol. 2011;106:199-12.View Article PubMed
  20.Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis. 2000;32:769-74.View Article PubMed
  21.Lochs H. Enteral nutrition—the new maintenance therapy in Crohn’s disease? Inflamm Bowel Dis. 2007;13:1581-582.View Article PubMed
  
• 作者单位：Noriko Kamata (1)
  Nobuhide Oshitani (2)
  Kenji Watanabe (3)
  Kimihiko Watanabe (1)
  Shuhei Hosomi (1)
  Atsushi Noguchi (1)
  Tomomi Yukawa (1)
  Hirokazu Yamagami (1)
  Matsatsugu Shiba (1)
  Tetsuya Tanigawa (1)
  Toshio Watanabe (1)
  Kazunari Tominaga (1)
  Yasuhiro Fujiwara (1)
  Tetsuo Arakawa (1)
  
  1. Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan
  2. Department of Medicine, Social Welfare Service Corporation, Ishii Memorial Aizen-en, Aizeznbashi Hospital, 5-16-15, Nihonbashi, Naniwa-ku, Osaka, 595-0029, Japan
  3. Department of Gastroenterology, Osaka City General Hospital, 2-13-22, Miyakojima Hondouri, Miyakojima-ku, Osaka, 534-0021, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Hepatology
  Oncology
  Transplant Surgery
  Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-2568

文摘

Background Loss of response (LOR) to infliximab (IFX) has become an important clinical issue for patients with Crohn’s disease (CD). Elemental diet (ED) therapy has been established as a nutrition therapy for CD in Japan. ED therapy can reduce antigen exposure and is both efficacious and safe. Aim To evaluate the efficacy of concomitant ED therapy in maintaining regular IFX infusion in patients with CD. Methods We retrospectively studied 125 patients with luminal CD treated with scheduled IFX maintenance therapy with a regular dosage. Patients were classified into two groups: the ED group with intake ?00?kcal/day and the non-ED group with intake <900?kcal/day. When clinical LOR was detected on the basis of disease activity, laboratory parameters, or endoscopic findings, the physician discontinued the infusion schedule of IFX. We investigated the efficacy of ED therapy for sustaining the scheduled IFX maintenance therapy. Results With the exception of ED intake, no significant differences were found in patient characteristics between the ED group and the non-ED group. The ED group was significantly superior to the non-ED group (p?=?0.049) in sustaining scheduled IFX maintenance therapy. It is well known that ED therapy is more effective for small bowel lesions than colonic lesions in CD. When comparing ileitis and ileocolitis patients with CD, the ED group was significantly superior to the non-ED group (p?=?0.015). Conclusions Concomitant ED therapy is effective in maintaining scheduled IFX maintenance therapy in patients with luminal CD in order to prevent LOR.